At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NDRA ENDRA Life Sciences Inc
Trading 11-15 12:50:13 EST
4.55
-0.75
-14.15%
High5.33Low4.40Vol105.50K
Open5.24D1 Closing5.30Amplitude17.55%
Mkt Cap2.42MTradable Cap2.36MTotal Shares531.19K
T/O511.66KT/O Rate20.36%Tradable Shares518.19K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
ENDRA Life Sciences Q3 EPS $(9.54)
Benzinga  ·  11-15 22:25
ENDRA Life Sciences Q3 EPS $(9.54)
ENDRA Life Sciences Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters  ·  11-15 23:53
ENDRA Life Sciences Inc reports results for the quarter ended September 30 - Earnings Summary
ENDRA Life Sciences Inc: Qtrly Loss per Share $9.54
THOMSON REUTERS  ·  11-15 22:24
ENDRA Life Sciences Inc: Qtrly Loss per Share $9.54
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
THOMSON REUTERS  ·  11-15 22:24
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
Press Release: ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
Dow Jones  ·  11-15 22:24
Press Release: ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024
Business Wire  ·  11-12
Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024
ENDRA Life Sciences Inc expected to post a loss of $62.30 a share - Earnings Preview
Reuters  ·  11-08
ENDRA Life Sciences Inc expected to post a loss of $62.30 a share - Earnings Preview
ENDRA Life Sciences Inc trading halted, news pending
TIPRANKS  ·  11-07
ENDRA Life Sciences Inc trading halted, news pending
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent
Business Wire  ·  11-06
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent
ENDRA Life Sciences Shares Soar After Launch of Postmarket Trial for TAEUS Liver System
MT Newswires Live  ·  10-23
ENDRA Life Sciences Shares Soar After Launch of Postmarket Trial for TAEUS Liver System
BRIEF-Endra Life Sciences Activates Taeus System To Initiate Clinical Study At Lmu University Hospital In Germany
Reuters  ·  10-22
BRIEF-Endra Life Sciences Activates Taeus System To Initiate Clinical Study At Lmu University Hospital In Germany
ENDRA Life Sciences Activates Taeus System to Initiate Clinical Study at Lmu University Hospital in Germany
THOMSON REUTERS  ·  10-22
ENDRA Life Sciences Activates Taeus System to Initiate Clinical Study at Lmu University Hospital in Germany
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany
Business Wire  ·  10-22
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany
ENDRA Life Sciences Strives for Nasdaq Compliance
TIPRANKS  ·  08-29
ENDRA Life Sciences Strives for Nasdaq Compliance
ENDRA Life Sciences granted extension to regain compliance with Nasdaq continued listing requirements
seekingalpha  ·  08-29
ENDRA Life Sciences granted extension to regain compliance with Nasdaq continued listing requirements
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements
Business Wire  ·  08-29
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements
ENDRA Life Sciences Discusses Quarterly Results in Call
TIPRANKS  ·  08-24
ENDRA Life Sciences Discusses Quarterly Results in Call
Endra Life Sciences GAAP EPS of -$0.08 misses by $0.01
seekingalpha  ·  08-23
Endra Life Sciences GAAP EPS of -$0.08 misses by $0.01
ENDRA Life Sciences Q2 2024 GAAP EPS $(0.08) Misses $(0.04) Estimate
Benzinga  ·  08-23
ENDRA Life Sciences Q2 2024 GAAP EPS $(0.08) Misses $(0.04) Estimate
ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update
THOMSON REUTERS  ·  08-23
ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

Introduction

Company Name.
ENDRA Life Sciences Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Issue price:
--